Shop Now Contact

Anti-Human TNF alpha (Infliximab Biosimilar)

Cat # Size Price Quantity
5033011 mg$125
5033025 mg$400
50330320 mg$800

  Bulk/Custom

Product Details

CloneInfliximab
ApplicationNeutralization, Intracellular Flow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionInfliximab Biosimilar, TNF alpha Monoclonal Antibody
IsotypeHuman IgG1
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenRecombinant human TNF protein
Clone NumbercA2
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Min Sample Size1 mg
Storage Conditions4ºC
Maximal Shelf Life12 months
SynonymsTNFa
Target NameTNFα
Research AreasCytokines, Monocytes, Macrophages, Neutrophils, T cells, Inflammation, Autoimmunity
See All FormatsClone Infliximab

Background Information

Infliximab is a chimeric monoclonal antibody belonging to the immunoglobulin G1 kappa (IgG1κ) subclass, engineered to specifically bind and neutralize tumor necrosis factor-alpha (TNF-α), a proinflammatory cytokine. Structurally, Infliximab is a glycoprotein with a molecular weight of approximately 149 kilodaltons (kDa). It is composed of two identical heavy chains and two identical light chains connected by disulfide bonds, forming the characteristic Y-shaped antibody structure. The molecule combines murine (mouse-derived) variable regions with human constant regions, thereby retaining antigen specificity while exhibiting improved molecular compatibility with human immune system components. It is expressed in mammalian cell systems, such as Chinese Hamster Ovary (CHO) cells, to ensure proper folding, disulfide linkage formation, and glycosylation.

The antigen-binding fragments (Fab) of Infliximab contain complementarity-determining regions (CDRs) within the variable domains of both heavy (VH) and light (VL) chains. These CDRs form a high-affinity binding site that specifically recognizes and binds to soluble and transmembrane forms of TNF-α. The binding interface is stabilized by hydrogen bonds and hydrophobic interactions, producing nanomolar-level affinity. By occupying key epitopes on TNF-α, Infliximab prevents it from engaging its native receptors (TNFR1 and TNFR2) on target cells, thereby inhibiting downstream signaling cascades such as the NF-κB and MAPK pathways, which regulate cytokine production, apoptosis, and cell activation in experimental systems.

The Fc (fragment crystallizable) region of the human IgG1 portion provides Infliximab with structural stability, extended serum half-life through neonatal Fc receptor (FcRn) recycling, and the potential for engaging Fc gamma receptors (FcγRs). This enables effector mechanisms such as complement activation and antibody-dependent cellular cytotoxicity (ADCC) in vitro. Overall, Infliximab represents a rationally designed chimeric IgG1 antibody that combines specific cytokine neutralization with structural robustness, an essential model for exploring antibody-mediated modulation of immune signaling pathways in biochemical and cellular research.

Data Sheets

Anti-Human TNF alpha (Infliximab Biosimilar) TDS

Related Products

Anti-Human TNFα (Adalimumab Biosimilar), Clone Adalimumab

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.